CD200 and neoplasm: To further understand the role of DDX39 in ccRCC tumor immunity, we performed Pearson's correlation analysis to determine the correlation of DDX39 expression with a series of immune cell markers, and found that DXX39 was associated with a variety of coinhibitory immune receptor markers in ccRCC patients, including PD-1, CD38, LAG3, LGALS9, KLRD1, TNFRSF4, FCRL4 and CD200.